September 26, 2023

Manuscript: Characterization and optimization of variability in a human colonic epithelium culture model

Learn about reproducibility and robustness of RepliGut® Planar Transverse colon model in this manuscript describing systematic testing of variables associated with model performance. This paper describes results from over 50 independent runs from 4 donor-derived starting intestinal stem cell cultures looking at passage number, TEER consistency, barrier formation kinetics, and response to proinflammatory cytokines. Published September 2023.

September 13, 2023

Poster: Genomic evaluation of RepliGut Planar Jejunum in response to metabolic inducers

Scientist Jarrett Bilton, PhD recently travelled to the 25th North American ISSX conference in Boston. In collaboration with researchers at Genentech, RepliGut® Planar Jejunum was evaluated for gene expression patterns in response to prototypical metabolic inducers Rifampin, CITCO, 3-MC, and Calcitriol. Poster shows the suitability of RepliGut® Planar Jejunum for studying the contribution of intestinal epithelial cells to drug-drug interactions.

September 5, 2023

Poster: Characterization of biological variability in a stem cell-derived human intestinal epithelium model

Associate Director Liz Boazak recently travelled to the 2nd MPS World Summit held in Berlin, Germany June 25-29, 2023. Her poster was presented in the Reproducibility topic session and describes characterizing multiple donor and batch statistics of baseline RepliGut® Planar- transverse colon. Poster further describes how minimizing the variability improves ability to discern true biological responses to inflammatory insults.

July 27, 2023

Manuscript: NSAID-Induced Leaky Gut Modeled Using Polarized Monolayers of Primary Human Intestinal Epithelial Cells

Author Andrea Bhatt and colleagues used monolayer of intestinal epithelial cells to show that exposure to NSAIDs at physiologically relevant doses can cause changes in permeability in small intestine. This article highlights the potential utility of RepliGut® Planar for assessing toxicity of dietary factors, bacterial metabolites, or therapeutics.

July 27, 2023

Poster: Characterization of a novel human primary intestinal epithelial monolayer platform in response to a cytokine challenge

Clara Jundt and her team at Janssen R&D, in collaboration with Altis and UNC-Chapel Hill, conducted a study using human primary intestinal epithelial cells from multiple donors. Their aim was to determine if these cells could mimic a similar response and capture the genetic variability found in humans. The researchers treated the models with TNFα and IFNγ, revealing consistent responses across different donors. Additionally, they discovered that the JAK-STAT inhibitor tofactinib effectively blocked these responses in a dose-dependent manner.